150 related articles for article (PubMed ID: 37427101)
1. Targeted treatment in a case series of AR+, HRAS/PIK3CA co-mutated salivary duct carcinoma.
Rieke DT; Schröder S; Schafhausen P; Blanc E; Zuljan E; von der Emde B; Beule D; Keller U; Keilholz U; Klinghammer K
Front Oncol; 2023; 13():1107134. PubMed ID: 37427101
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer.
Dalin MG; Desrichard A; Katabi N; Makarov V; Walsh LA; Lee KW; Wang Q; Armenia J; West L; Dogan S; Wang L; Ramaswami D; Ho AL; Ganly I; Solit DB; Berger MF; Schultz ND; Reis-Filho JS; Chan TA; Morris LG
Clin Cancer Res; 2016 Sep; 22(18):4623-33. PubMed ID: 27103403
[TBL] [Abstract][Full Text] [Related]
3. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.
van Boxtel W; Locati LD; van Engen-van Grunsven ACH; Bergamini C; Jonker MA; Fiets E; Cavalieri S; Tooten S; Bos E; Quattrone P; Verhaegh GW; Schalken JA; Licitra L; van Herpen CML;
Eur J Cancer; 2019 Mar; 110():62-70. PubMed ID: 30771738
[TBL] [Abstract][Full Text] [Related]
5. Targeted molecular profiling of salivary duct carcinoma with rhabdoid features highlights parallels to other apocrine and discohesive neoplasms: which phenotype should drive classification?
Rooper LM; Gagan J; Bishop JA
Head Neck Pathol; 2022 Dec; 16(4):1063-1072. PubMed ID: 35794510
[TBL] [Abstract][Full Text] [Related]
6. Androgen Deprivation Therapy for Patients with Androgen-Receptor-Positive Metastatic Salivary Duct Carcinoma: A Case Report and Review of the Literature.
You Y; Wang P; Wan X; Xu L; Gong Y; Zhang W
Onco Targets Ther; 2021; 14():3481-3486. PubMed ID: 34093024
[TBL] [Abstract][Full Text] [Related]
7. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance.
Xu B; Dogan S; Haroon Al Rasheed MR; Ghossein R; Katabi N
Hum Pathol; 2019 Nov; 93():30-36. PubMed ID: 31430492
[TBL] [Abstract][Full Text] [Related]
8. A Pitfall of the Androgen Deprivation Therapy for Salivary Duct Carcinoma: Hormonal Therapy-Induced Castrate-Resistant Prostate Cancer.
Yajima S; Nakanishi Y; Matsumoto S; Tanabe K; Masuda H
J Maxillofac Oral Surg; 2022 Dec; 21(4):1097-1100. PubMed ID: 36896090
[TBL] [Abstract][Full Text] [Related]
9. Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.
Kawakita D; Nagao T; Takahashi H; Kano S; Honma Y; Hirai H; Saigusa N; Akazawa K; Tani K; Ojiri H; Tsukahara K; Ozawa H; Okami K; Kondo T; Togashi T; Fushimi C; Shimura T; Shimizu A; Okamoto I; Okada T; Imanishi Y; Watanabe Y; Otsuka K; Sakai A; Ebisumoto K; Sato Y; Yamazaki K; Ueki Y; Hanazawa T; Saito Y; Ando M; Matsuki T; Nakaguro M; Sato Y; Urano M; Utsumi Y; Kohsaka S; Saotome T; Tada Y
Ther Adv Med Oncol; 2022; 14():17588359221119538. PubMed ID: 36090801
[TBL] [Abstract][Full Text] [Related]
10. Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
van Boxtel W; Verhaegh GW; van Engen-van Grunsven IA; van Strijp D; Kroeze LI; Ligtenberg MJ; van Zon HB; Hendriksen Y; Keizer D; van de Stolpe A; Schalken JA; van Herpen CM
Int J Cancer; 2020 Jun; 146(11):3196-3206. PubMed ID: 31745978
[TBL] [Abstract][Full Text] [Related]
11. Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.
Hanna GJ; Guenette JP; Chau NG; Sayehli CM; Wilhelm C; Metcalf R; Wong DJ; Brose M; Razaq M; Pérez-Ruiz E; Cohen EEW; Aggarwal R; Scholz C; Gualberto A; Ho AL
Cancer; 2020 Sep; 126(17):3972-3981. PubMed ID: 32557577
[TBL] [Abstract][Full Text] [Related]
12. Biomarker immunoprofile and molecular characteristics in salivary duct carcinoma: clinicopathological and prognostic implications.
Santana T; Pavel A; Martinek P; Steiner P; Grossmann P; Baněčková M; Skálová A
Hum Pathol; 2019 Nov; 93():37-47. PubMed ID: 31437521
[TBL] [Abstract][Full Text] [Related]
13. Integrative genomic analysis of salivary duct carcinoma.
Kim Y; Song S; Lee M; Swatloski T; Kang JH; Ko YH; Park WY; Jeong HS; Park K
Sci Rep; 2020 Sep; 10(1):14995. PubMed ID: 32929114
[TBL] [Abstract][Full Text] [Related]
14. Molecular characterization of apocrine salivary duct carcinoma.
Chiosea SI; Williams L; Griffith CC; Thompson LD; Weinreb I; Bauman JE; Luvison A; Roy S; Seethala RR; Nikiforova MN
Am J Surg Pathol; 2015 Jun; 39(6):744-52. PubMed ID: 25723113
[TBL] [Abstract][Full Text] [Related]
15. The tumor immune contexture of salivary duct carcinoma.
Schvartsman G; Bell D; Rubin ML; Tetzlaff M; Hanna E; Lee JJ; Weber R; Phan J; Glisson BS; Ferrarotto R
Head Neck; 2021 Apr; 43(4):1213-1219. PubMed ID: 33576119
[TBL] [Abstract][Full Text] [Related]
16. Molecular patterns in salivary duct carcinoma identify prognostic subgroups.
Mueller SA; Gauthier MA; Blackburn J; Grady JP; Kraitsek S; Hajdu E; Dettmer MS; Dahlstrom JE; Lee CS; Luk PP; Yu B; Giger R; Kummerfeld S; Clark JR; Gupta R; Cowley MJ
Mod Pathol; 2020 Oct; 33(10):1896-1909. PubMed ID: 32457410
[TBL] [Abstract][Full Text] [Related]
17. Genomic alteration in rare subtype of sarcomatoid salivary duct carcinoma.
Jeong JS; Cho KJ; Kim D; Lee YS; Song JS
Pathol Res Pract; 2021 Dec; 228():153678. PubMed ID: 34781210
[TBL] [Abstract][Full Text] [Related]
18. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
[TBL] [Abstract][Full Text] [Related]
19. First Line Androgen Deprivation Therapy vs. Chemotherapy for Patients With Androgen Receptor Positive Recurrent or Metastatic Salivary Gland Carcinoma-A Retrospective Study.
Viscuse PV; Price KA; Garcia JJ; Schembri-Wismayer DJ; Chintakuntlawar AV
Front Oncol; 2019; 9():701. PubMed ID: 31428578
[No Abstract] [Full Text] [Related]
20. Combined androgen deprivation therapy in recurrent androgen-receptor-positive salivary duct carcinoma - a case report and review of the literature.
Poxleitner P; Shoumariyeh K; Steybe D; Hupfer V; Voss PJ; Rawluk J; Ermer M; Miething C; Schmelzeisen R; Duyster J
J Stomatol Oral Maxillofac Surg; 2020 Nov; 121(5):599-603. PubMed ID: 31904529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
